Media Coverage

A study of 10 people with Parkinson's disease and 10 healthy controls found differences in how brain activity varied across walking phases while patients were on medication and receiving deep brain stimulation at their usual clinical settings. Researchers simultaneously recorded EEG, subthalamic nucleus signals, and whole-body movement, analyzing only straight walking segments. Group differences were limited in averaged spectra, but step-by-step analysis revealed prominent high-beta and gamma timing differences and gait-cycle modulation in the subthalamic nucleus. These signals are not yet established biomarkers of impaired gait; their relationships with walking speed, stride length, and step-to-step variability still need testing. This study is a preprint and has not been peer reviewed.

A study in healthy adults compared flickering disks filled with Gabor textures against plain flickering disks. An initial frequency sweep involved 24 participants; analysis of a five-target task two months later included 18 of them. Textured flicker produced higher EEG signal-to-noise ratios at 3-9 Hz and was rated more comfortable and less fatiguing at every tested frequency. In offline classification of the five-target task, textured flicker performed well at 5-7 Hz, while plain flicker was more reliable at 14-16 Hz. Accuracy was comparable within each stimulus's preferred band. Better comfort therefore did not mean better decoding at every frequency.

Arbor Neuroscience plans to develop brain maps that track signal changes after neuromodulation and connect specific symptoms with neural circuits. Its goal is to guide treatment targeting by symptoms rather than diagnostic categories alone. Its predecessor, Forest Neurotech, developed Forest 17, a wearable functional ultrasound imaging device that observes brain activity through localized blood flow changes. A future version is intended to add focused ultrasound neuromodulation. These are research instruments for people who already have ultrasound-transparent skull-replacement implants, not devices that anyone can simply put on and use. Symptom-to-circuit mapping and treatment planning based on it remain organizational goals.

Paradromics has named William J. Marks chief clinical officer; he brings nearly three decades of experience in clinical neuroscience and implantable devices. The appointment comes as the company advances Connect-One, an early feasibility study of its Connexus BCI system, which is intended to restore communication for people who have lost it to spinal cord injury, stroke or ALS.